The contribution of some biologically active substances of adipose tissue to the development of cardiovascular complications in comorbid patients

Prof. Kravchun P.P., Assoc.prof. Yakovenko O.L., Assoc.prof. Dunaieva I.P., prof. Kravchun N.O.

Kharkiv National Medical University

 The contribution of some biologically active substances of adipose tissue to the development of cardiovascular complications in comorbid patients. Adipose tissue hormones — adipokines — vaspin and omentin, which control homeostasis, lipid and glucose metabolism, have attracted scientific interest in recent years. The purpose of the study was to determine the contribution of some hormones of adipose tissue, namely, vaspin and omentin, in the development of obesity in patients with coronary heart disease with concomitant obesity. Materials and methods. A comprehensive examination of 38 patients with coronary heart disease in combination with obesity (average age: 64±1.9 years), men and women in equal numbers, was conducted; the comparison group consisted of 40 patients with coronary artery disease without obesity. Control group: 20 practically healthy individuals without coronary heart disease and with normal body weight, average age 58.2±1.4 years. Conclusions: The comorbidity of coronary heart disease and obesity leads to the activation of the pro-inflammatory hormone of adipose tissue — vaspin and insufficient circulation of omentin, which leads to an increase in body weight. The development of obesity in patients with coronary heart disease depends on the dysfunction of adipose tissue, the manifestations of which are an imbalance in the levels of vaspin and omentin.

Keywords: adipokines, obesity, coronary heart disease.

https://doi.org/10.15407/internalmed2023.01.088

Download.PDF (ukr)

Cite:

Кравчун, П.П. Внесок деяких біологічно активних речовин жирової тканини в розвиток серцево-судинних ускладнень у коморбідних пацієнтів / П.П. Кравчун, О.Л. Яковенко, І.П. Дунаєва, Н.О. Кравчун // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2023. – № 1. – С. 88-91. doi: 10.15407/internalmed2023.01.088

Kravchun PP, Yakovenko OL, Dunaieva IP, Kravchun NO. Vnesok deiakykh biolohichno aktyvnykh rechovyn zhyrovoi tkanyny v rozvytok sertsevo-sudynnykh uskladnen u komorbidnykh patsiientiv [The contribution of some biologically active substances of adipose tissue to the development of cardiovascular complications in comorbid patients]. Shidnoevr. z. vnutr. simejnoi med. 2023;1:88-91. Ukrainian. doi: 10.15407/internalmed2023.01.088

Reference

  1. Luo L, Liu M. Adipose tissue in control of metabolism. Journal of Endocrinology. 2016;231(3):R77-R99. http://dx.doi.org/10.1530/joe-16-0211
  2. Bakirci E, Degirmenci H, Duman H, Inci S, Hamur H, Buyuklu M, Ceyhun G, Topal E. Increased Epicardial Adipose Tissue Thickness is Associated With Angiographic Thrombus Burden in the Patients With Non-ST-Segment Elevation Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis. 2014;21(7):612-618. http://dx.doi.org/10.1177/1076029614558113
  3. Migliaccio S, Greco E, Wannenes F, Donini L, Lenzi A. Adipose, bone and muscle tissues as new endocrine organs: role of reciprocal regulation for osteoporosis and obesity development. Hormone Molecular Biology and Clinical Investigation. 2014;17(1):. http://dx.doi.org/10.1515/hmbci-2013-0070
  4. Morel S, Kwak B, Rohner-Jeanrenaud F, Steffens S, Molica F. Adipokines at the crossroad between obesity and cardiovascular disease. Thrombosis and Haemostasis. 2015;113(03):553-566. http://dx.doi.org/10.1160/th14-06-0513
  5. Khan M, Joseph F. Adipose Tissue and Adipokines: The Association with and Application of Adipokines in Obesity. Scientifica. 2014;2014:1-7. http://dx.doi.org/10.1155/2014/328592
  6. Kadoglou N, Vrabas I, Kapelouzou A, Lampropoulos S, Sailer N, Kostakis A, Liapis C. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regulatory Peptides. 2011;170(1-3):57-61. http://dx.doi.org/10.1016/j.regpep.2011.05.008
  7. Britton K, Fox C. Perivascular adipose tissue and vascular disease. Clinical Lipidology. 2011;6(1):79-91. http://dx.doi.org/10.2217/clp.10.89
  8. Walaa M, Ashraf I, Zeinab A, Dalia H. Changes of serum omentin-1 levels and relationship between omentin-1 and insulin resistance in chronic hepatitis c patients. EXCLI Journal. 2013;12:924–932.
  9. Kovacs P, Miehle K, Sandner B, Stumvoll M, Blüher M. Insulin Administration Acutely Decreases Vaspin Serum Concentrations in Humans. Obesity Facts. 2013;6(1):86-88. http://dx.doi.org/10.1159/000348836
  10. Heiker J, Klöting N, Kovacs P, Kuettner E, Sträter N, Schultz S, Kern M, Stumvoll M, Blüher M, Beck-Sickinger A. Vaspin inhibits kallikrein 7 by serpin mechanism. Cellular and Molecular Life Sciences. 2013;70(14):2569-2583. http://dx.doi.org/10.1007/s00018-013-1258-8
  11. Li Z, Ma C, Li L, Pan X, Chen L. Vaspin Serum Concentration in Patients with Type 2 Diabetes and Carotid Plaque. Journal of International Medical Research. 2012;40(5):1670-1676. http://dx.doi.org/10.1177/030006051204000506
  12. Li H, Zhang H, Jian W, Li Q, Peng W, Xu Y. Association of vaspin gene polymorphisms with coronary artery disease in Chinese population and function study. Clinica Chimica Acta. 2013;415:233-238. http://dx.doi.org/10.1016/j.cca.2012.10.042
  13. El-Mesallamy H, El-Derany M, Hamdy N. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabetic Medicine. 2011;28(10):1194-1200. http://dx.doi.org/10.1111/j.1464-5491.2011.03353.x
  14. de Souza Batista C, Yang R, Lee M, Glynn N, Yu D, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried S, Gong D, Shuldiner A, Pollin T, McLenithan J. Omentin Plasma Levels and Gene Expression Are Decreased in Obesity. Diabetes. 2007;56(6):1655-1661. http://dx.doi.org/10.2337/db06-1506
  15. Eisinger K, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer M, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. European Journal of Clinical Investigation. 2013;43(9):926-932. http://dx.doi.org/10.1111/eci.12122
  16. Pan H, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Research and Clinical Practice. 2010;88(1):29-33. http://dx.doi.org/10.1016/j.diabres.2010.01.013
  17. Zhang Y, Zhou L. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. European Journal of Pharmacology. 2013;698(1-3):137-144. http://dx.doi.org/10.1016/j.ejphar.2012.11.016
  18. Kirnap N, Gursoy G, Esbah O, Acar Y, Demirbas B. The Relationship between Plasma Omentin Levels and Insulin Resistance in Newly Diagnosed Type 2 Diabetic Patients.. The Endocrine Society’s 92nd Annual Meeting, June 19–22, 2010 – San Diego. 2010;:P1-497-P1-497. http://dx.doi.org/10.1210/endo-meetings.2010.part1.p10.p1-497
  19. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of Serum Omentin Levels and Relationship between Omentin and Adiponectin Concentrations in Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. 2011;119(04):257-263. http://dx.doi.org/10.1055/s-0030-1269912
  20. Moreno-Navarrete J, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real J. Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity. 2011;19(8):1552-1559. http://dx.doi.org/10.1038/oby.2010.351
  21. Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. Journal of Sports Sciences. 2010;28(9):993-998. http://dx.doi.org/10.1080/02640414.2010.484070
  22. Tan B, Adya R, Farhatullah S, Lewandowski K, O’Hare P, Lehnert H, Randeva H. Omentin-1, a Novel Adipokine, Is Decreased in Overweight Insulin-Resistant Women With Polycystic Ovary Syndrome. Diabetes. 2008;57(4):801-808. http://dx.doi.org/10.2337/db07-0990
  23. Youn B, Klöting N, Kratzsch J, Lee N, Park J, Song E, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Blüher M. Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes. Diabetes. 2008;57(2):372-377. http://dx.doi.org/10.2337/db07-1045
  24. Barth S, Klein P, Horbach T, Dötsch J, Rauh M, Rascher W, Knerr I. Expression of Neuropeptide Y, Omentin and Visfatin in Visceral and Subcutaneous Adipose Tissues in Humans: Relation to Endocrine and Clinical Parameters. Obesity Facts. 2010;3(4):245-251. http://dx.doi.org/10.1159/000319508
  25. Batra A, Siegmund B. The Role of Visceral Fat. Digestive Diseases. 2012;30(1):70-74. http://dx.doi.org/10.1159/000335722
  26. Choi J, Rhee E, Kim K, Woo H, Lee W, Sung K. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. European Journal of Endocrinology. 2011;165(5):789-796. http://dx.doi.org/10.1530/eje-11-0375
  27. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer A. Increased Chemerin and Decreased Omentin-1 in Both Adipose Tissue and Plasma in Nascent Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2013;98(3):E514-E517. http://dx.doi.org/10.1210/jc.2012-3673